Cavitation Technologies, Inc. (CVAT): Entry into a Material Definitive Agreement

Cavitation Technologies, Inc. (CVAT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Cavitation Technologies, Inc. Executes Definitive Purchase Agreement with European Guarantee Services S.à.r.l CHATSWORTH, CA – August 17, 2026 (GLOBE NEWSWIRE) – Cavitation Technologies, Inc. (OTCQB: CVAT) ("CVAT" or the "Company"), a leading provider of sustainable

Original reporting
Published Aug 19, 2026, 6:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 6:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$CVAT
Bullish
high confidence
Mentioned
$CVAT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CVATBullishHigh
01

Why it matters

The disclosed offer price of $0.108 per share creates a clear price floor, likely driving the stock toward that level while the tender period remains open.

02

Market read

Primary disclosure of a cash tender offer for a micro‑cap stock, offering immediate trading action.

03

What to watch

Potential regulatory review of the cross‑border purchaser and the contingent Alchemy acquisition.

Relevance 6/10Novelty 8/10Timing: post‑filing today (Aug 19 2026)

Background

Cavitation Technologies, Inc. (CVAT) filed a Form 8‑K reporting a tender offer by European Guarantee Services S.A.R.L. to purchase all shares for $35 M cash.

Company-level read

Ticker impact

$CVATBullishHigh confidence
Context

SEC 8‑K filing announces a $35 M cash tender offer to acquire all outstanding CVAT shares at $0.108 per share.

Expected impact

Short‑term upside as tender offer price exceeds market; volatility expected until offer expires.

Evidence & confidence

Tender offer price is disclosed and higher than recent trading levels, creating immediate arbitrage opportunity.

Market effects

May signal consolidation interest in the niche cavitation technology sector.

Limited to U.S. micro‑cap market; no broader regional effect.

Low; primarily affects CVAT shareholders.

Counterpoint

If the offer price undervalues future growth, shareholders may reject, causing price weakness.

Key entities

  • Cavitation Technologies, Inc.

    Target of the tender offer.

  • European Guarantee Services S.A.R.L.

    Purchaser proposing the cash acquisition.

Related articles

$CVSHigh

Cordavis to stay in CVS Health after bifurcation of $117bn empire

CVS Health will retain its biosimilar subsidiary Cordavis after splitting into two publicly traded entities by 2028. The company, with a market cap of around $117bn, will separate its healthcare solutions business from its retail pharmacy chain. Cordavis, established in 2023, markets five biosimilars and aims to reduce drug costs. CVS Health confirmed Cordavis will remain with the healthcare solutions company post-split.

$AAPLLow

Apple Proposes Seven-Series Senior Notes Amid AI Data-Center Buildout

Apple filed a preliminary prospectus for seven series of senior unsecured notes, with proceeds earmarked for general corporate purposes, including capital expenditures and shareholder returns. The notes include floating and fixed-rate series maturing between 2028 and 2036. Apple reported $78.1 billion in outstanding unsecured senior notes as of September 26, 2026.

$WENMed

Wendy's Rejects Trian Takeover; Adopts Poison Pill

Wendy's rejected a $7.35 per share takeover offer from Trian and allies, calling it undervalued. The board adopted a poison pill to deter a hostile takeover. Q3 same-store sales fell, but earnings and revenue beat estimates. Shares dipped 1% in premarket trading.